
Immatics NV (IMTX) Stock Forecast & Price Target
Immatics NV (IMTX) Analyst Ratings
Bulls say
Immatics is well-positioned for success due to its strong financial position with $505.8 million in cash, providing operational runway until 2H27, and its promising pipeline of T-cell redirecting immunotherapies for the treatment of various cancers. Despite clinical risks and regulatory unknowns, the company's potential for global sales of €573.7 million by 2035E and a 25% PoS for IMA402 in melanoma and ovarian cancer support a BUY rating with a PT of $19/share.
Bears say
Immatics is heavily dependent on its clinical pipeline, which may not be as strong as initially thought. The company also faces significant competition from other players in the T-cell therapy space, as well as potential competition from other modalities. Additionally, the company may need to raise additional capital before reaching profitability, which could result in share dilution for shareholders.
This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.
Immatics NV (IMTX) Analyst Forecast & Price Prediction
Start investing in Immatics NV (IMTX)
Order type
Buy in
Order amount
Est. shares
0 shares